We came across a bullish paper from Bio-Techne Corporation (Tech) about ScuttleBlurb's alternative. In this article, we will summarize Bull's paper on technology. As of 28Th possible. According to Yahoo Finance, Tech's P/E is 57.75 and 22.03, respectively.
Close-up of a biotech machine working on tumor therapy.
Bio-Techne has built a diverse and complex business centered on its strong legacy of recombinant proteins, expanding downstream into antibodies, assays and instrumentation platforms, while also entering cell and gene therapy (CGT) solutions. Its revenue is roughly distributed between protein science and diagnosis, which are closely related to diagnosis - the identification of disease biomarkers and then make it a therapeutic target for development using biological-network proteins and antibodies. Despite about 20 acquisitions over the past decade, its core old products still account for 56% of total revenue, with the rest coming from faster-growing, less penetrating markets.
About half of Bio-Techne's revenue comes from commercial R&D, now dominated by smaller venture-invested biotechnology rather than large pharmaceutical companies, making the segment more cyclical. Academia accounts for another 20%, a price-sensitive group that is susceptible to budget fluctuations. The company gained a foundation for clinical and commercial use in GMP protein production, a highly regulated and profitable niche, although it lags behind leaders like Miltenyi and Cellgenix. Bio-Techne also extends to proteomics and space biology through acquisition.
Although the company once predicted revenue of nearly $2 billion by 2026, it grew at a rate due to several factors: COVID-related demand spikes followed by inventory sales, revenue in China fell by 20-30%, the decline in COVID testing has faded, and the cautious FDA OBSCHITED, CGTS hurt growth expectations. Although these setbacks have caused nearly 50% of stock prices to fall, recent signs have shown that the rebound in organic growth has recovered to 9% and improved instrument sales. Bio-Techne's broad strategy reflects its efforts to protect core franchises while expanding into new areas of growth, including becoming an instrument provider that captures more downstream value.
Bio-Techne Corporation (Tech) is not on our list The 30 Most Popular Stocks in Hedge Funds. According to our database, at the end of the first quarter, 34 hedge fund portfolios held technology in the previous quarter. Although we acknowledge that the risk and potential of technology is an investment, our belief lies in the belief that certain AI stocks have greater expectations and provide higher returns over a shorter time frame. If you are looking for AI stocks that are more promising than technology but have less than 5 times its gains, check out our report Cheapest AI stocks.